Bristol Myers Squibb (BMY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the ...

Looking for undervalued stocks? We identified the top undervalued stocks in March 2025. Check out the list here.

Healthcare is considered a defensive industry, since good medical care is needed regardless of economic or market conditions.

This was the stock's fifth consecutive day of gains.

Bristol-Myers Squibb released financial results for Q4 2024. Check out why I am upgrading BMY stock's rating from 'Buy' to ...

Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in two upcoming investor conferences in March 2025. The company will participate in a fireside chat at the TD Cowen ...

The FDA accepted a supplemental biologics license application for Opdivo plus Yervoy as a first-line treatment for some adult ...

Bristol Myers' Opdivo plus Yervoy gets FDA Priority Review for first-line MSI-H/dMMR metastatic colorectal cancer, with a ...

Bristol Myers said about 5% to 7% of people with metastatic colorectal cancer have microsatellite instability-high or mismatch-repair-deficient tumors, adding that these patients are less likely to ...

Squibb announced that the U.S. FDA has accepted the supplemental biologics license application for Opdivo plus Yervoy as a ...

In a regulatory filing on Friday night, Bristol Myers (BMY) disclosed that its CEO Christopher Boerner bought 2K shares of common stock on ...